Eli Lilly’s new oral weight-loss drug, orforglipron, is shaping up to be a game-changer in the world of obesity treatment. In a Phase 3 clinical trial presented at the 2025 American Diabetes Association conference and published in The New England Journal of Medicine, researchers found that the daily pill is nearly as effective as injectable drugs like Ozempic and Mounjaro in reducing weight and lowering blood sugar. And it might be available as soon as next year.
As Effective as Ozempic, Without the Needle
The 40-week trial involved 559 adults with type 2 diabetes and showed that participants taking orforglipron lost an average of 16 pounds (about 7.9% of their body weight) on the highest dose. They also saw their A1C levels — a key marker of blood sugar control — drop by as much as 1.6%. Up to 76% of participants reached the American Diabetes Association’s target A1C level of below 7%.
Dr. Julio Rosenstock, the trial’s lead investigator, called the results “clinically meaningful,” especially since improvements were seen in as little as four weeks. Importantly, orforglipron is a pill taken once daily, with no restrictions on food or water intake — a major convenience over injectable options.
Orforglipron, like Ozempic (semaglutide) and other GLP-1 receptor agonists, mimics a natural gut hormone that helps regulate appetite and blood sugar after eating. The key difference is that orforglipron is a small molecule and not a peptide, allowing it to be taken as a pill instead of an injection. The pill is also designed to be stable at room temperature, which eliminates the need for refrigerated storage — another advantage over injectables.
Ozempic works in a similar way, but as a peptide-based injectable, it requires cold-chain logistics and regular needle use, which some patients avoid due to discomfort or inconvenience.
Safety and Side Effects
Orforglipron’s safety profile is consistent with the GLP-1 class of drugs. The most common side effects were mild to moderate gastrointestinal issues like nausea, diarrhea, constipation, and indigestion — especially during dose escalation. Between 4% and 8% of users stopped the medication due to side effects, compared to just 1% in the placebo group.
No liver-related safety issues were reported, and the drug did not appear to cause excessive muscle loss — a concern with some weight-loss drugs, particularly in older adults.
Eli Lilly plans to submit orforglipron for regulatory approval for obesity treatment by the end of 2025 and for type 2 diabetes in 2026. The company has not yet disclosed the cost, but pills are generally cheaper to produce and easier to distribute than injectables, raising hopes that orforglipron could be more affordable and widely accessible.
Dr. Kenneth Custer, president of cardiometabolic health at Eli Lilly, emphasized the potential impact: “The efficacy, safety, and tolerability are really consistent with the very best injectable GLP-1s. We think this is a big deal.”
Why This Matters
Over 12% of American adults have tried weight-loss drugs like Wegovy, Zepbound, or Ozempic. But more than half stop taking them within a year due to cost, side effects, or supply issues. A convenient, effective pill could solve many of those problems, especially if it proves easier to stick with long-term.
Dr. Scott Hagan of the University of Washington explained, “The more options there are, the better we can tailor treatment. Not every drug works the same for every person.”
Orforglipron may also reduce logistical barriers in less developed countries that lack refrigeration infrastructure, making it a potential global solution for both obesity and type 2 diabetes.
Lilly is currently running more studies under its ATTAIN and ACHIEVE trial programs. These will further assess orforglipron’s safety and efficacy in broader populations, including people with obesity but without diabetes. Results are expected later this year.
If regulators approve it, orforglipron could arrive in pharmacies in 2026 — potentially reshaping the landscape of obesity treatment with a simple, daily pill.
